Altimmune, Inc. (ALT)
| Market Cap | 351.71M |
| Revenue (ttm) | 20,000 |
| Net Income (ttm) | -87.75M |
| Shares Out | 88.26M |
| EPS (ttm) | -1.17 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,090,459 |
| Open | 3.920 |
| Previous Close | 3.920 |
| Day's Range | 3.850 - 4.030 |
| 52-Week Range | 2.900 - 11.160 |
| Beta | 0.06 |
| Analysts | Strong Buy |
| Price Target | 16.50 (+314.05%) |
| Earnings Date | Nov 11, 2025 |
About ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland. [Read more]
Financial Performance
In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ALT stock is "Strong Buy." The 12-month stock price target is $16.5, which is an increase of 314.05% from the latest price.
News
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline
Altimmune allegedly misled investors on Pemvidutide's MASH trial, which failed its key fibrosis endpoint, causing shares to plunge 53% on June 26, 2025.
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquir...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful fra...
Altimmune to Participate in Two Upcoming Investor Conferences
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiomet...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options
Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT
NEW YORK , Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiomet...
Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Altimmune, Inc. (NASDAQ:ALT) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:45 AM EDT Company Participants Vipin Garg - President, CEO & Director M. Harris - Chief Medic...
Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)
Altimmune, Inc.'s pemvidutide shows competitive weight loss and MASH data, but missed a key fibrosis endpoint in a recent MASH study, causing downward share price volatility. Despite setbacks, pemvidu...
Altimmune to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) --...
Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)
PHILADELPHIA , Aug. 15, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company...
Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT) Q2 2025 Earnings Call August 12, 2025 8:30 AM ET Company Participants Gregory L. Weaver - Chief Financial Officer Scott Harris - Corporate Participant Vipin K.
These Analysts Slash Their Forecasts On Altimmune Following Q2 Results
Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday.
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically sig...
Altimmune Board of Directors Appoints Jerry Durso as Chairman
Appointment recognizes Mr. Durso's extensive commercial expertise as Altimmune prepares for Phase 3 development of pemvidutide in MASH
Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
GAITHERSBURG, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that it will report its second quarter 2025 financi...
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $ALT--ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm.
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometa...
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
On Thursday, Altimmune, Inc. ALT released topline results from the IMPACT Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH).
Altimmune: Deciphering The MASH Crash (Rating Upgrade)
Despite Altimmune, Inc.'s sharp selloff, I believe the market overreacted to pemvidutide's Phase IIb MASH data, which showed meaningful liver improvements and strong safety. The modest weight loss in ...
Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide
Altimmune, Inc.'s pemvidutide met the primary endpoint of MASH resolution in phase 2b IMPACT study which sets it on a continued development path going forward. The short 24-week trial duration likely ...